EASL 2014: Sofosbuvir + Simeprevir Shows High Cure Rates for Hep C Patients with or without Cirrhosis
- Category: Experimental HCV Drugs
- Published on Sunday, 13 April 2014 00:00
- Written by Liz Highleyman
A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of genotype 1 hepatitis C patients with either absent to moderate liver fibrosis or with advanced fibrosis or cirrhosis, according to data from the COSMOS trial presented last week at the 49th EASL International Liver Congress in London.